FDA grants priority review to Lovenox for new heart attack indication

Share this article:
Sanofi-Aventis has won FDA priority review for a new indication for its blockbuster blood thinner Lovenox. The FDA will review Lovenox for treatment of patients suffering acute ST-segment elevation myocardial infarction (STEMI). STEMI is a heart attack in which an artery is generally completely blocked for enough time to cause heart muscle damage. The blockage is caused by blood clot formation in the heart arteries. Sanofi-Aventis said it also submitted the drug for the new indication in European countries including the UK, Spain, France, Germany and Italy. Lovenox is currently approved by the FDA for seven indications for the prophylaxis and treatment of thromboembolic disease. Global sales of Lovenox were at $2.5 billion for 2005.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union